Beijing SL Pharmaceutical Co. Ltd. Class A

As of March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A carries a market capitalization of 7.80B, placing it among publicly traded companies globally. Its enterprise value stands at 6.65B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A has 1.03B shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 13.39, and the price-to-book ratio stands at 1.53.

These figures are as of March 31, 2026. The EV/Sales ratio of 10.96 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.65B versus a market cap of 7.80B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A maintains a current ratio of 3.38, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A posted a negative return on equity (ROE) of -8.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.67, reflecting losses generated across the asset base. The company generates approximately 677,755.84 in revenue per employee across its workforce of 895.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.56 indicates how many times Beijing SL Pharmaceutical Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A recorded 50.95M in income tax expense. The company reported a pretax loss of -404.54M and -453.36M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A's stock has declined approximately 30.84% over the past 52 weeks. The 50-day moving average sits at 5.83, while the 200-day moving average is 6.38.

Over the twelve months ended March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A generated 606.59M in revenue and converted that into -453.36M in net income, yielding earnings per share of -0.43. EBITDA reached -405.68M, while operating income came in at 30.99M.

These figures are as of March 31, 2026. Total book value stands at 5.10B, with working capital of 1.44B providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A posted a gross margin of 63.19, reflecting its pricing power and cost economics. The operating margin of 5.11 and net profit margin of -74.74 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of 0.58 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Beijing SL Pharmaceutical Co. Ltd. Class A's most recent stock split took place on July 4, 2019 with a 2:3 split ratio.

As of March 31, 2026, Beijing SL Pharmaceutical Co. Ltd. Class A has an Altman Z-Score of 7.89, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.